IVDA
Iveda Solutions, Inc.
There isn't enough reported data to score IVDA yet.
RKLB
Rocket Lab USA, Inc.
RKLB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
IVDA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
IVDA's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
IVDA PE Valuation
IVDA has no meaningful PE right now: it lost money over the past year.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
IVDA Forward outlook
There aren't enough analyst estimates for IVDA to show an outlook.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
IVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.53 | +$0.88 |
| Q1 2026 | -$0.66 | +$0.79 |
| Q4 2025 | -$0.88 | +$0.85 |
| Q3 2025 | -$1.22 | +$0.32 |
| Q2 2025 | -$1.41 | +$0.27 |
| Q1 2025 | -$1.45 | +$0.39 |
| Q4 2024 | -$1.73 | -$0.13 |
| Q3 2024 | -$1.54 | +$0.06 |
IVDA has the edge over RKLB on earnings, with more consistent year-over-year improvement.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
IVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $801.8K | -48% |
| Q1 2026 | $1.5M | +1.3% |
| Q4 2025 | $626K | -64% |
| Q3 2025 | $1.7M | -31% |
| Q2 2025 | $1.5M | -0.4% |
| Q1 2025 | $1.5M | +325% |
| Q4 2024 | $1.7M | +70% |
| Q3 2024 | $2.4M | +175% |
IVDA's revenue has slid since its 2024 peak: $801,846 last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -89% | -54 points |
| Q1 2026 | -38% | +19 points |
| Q4 2025 | -263% | -160 points |
| Q3 2025 | -13% | +12 points |
| Q2 2025 | -35% | -1.3 points |
| Q1 2025 | -57% | +278 points |
| Q4 2024 | -103% | +7.4 points |
| Q3 2024 | -25% | +79 points |
IVDA's operating margin was −89% last quarter, down 54 points from the same quarter a year ago.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over IVDA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB has the edge over IVDA on profitability, with a higher operating margin.
IVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$927.1K | -$801.2K |
| Q3 2025 | -$317K | +$582.7K |
| Q2 2025 | -$1.3M | -$325.9K |
| Q1 2025 | -$126K | +$1.2M |
| Q4 2024 | -$1.2M | -$236.5K |
| Q3 2024 | -$899.7K | +$2M |
| Q2 2024 | -$1M | -342% |
| Q1 2024 | -$1.3M | -$1.3M |
IVDA has the stronger cash trend. Its trailing FCF is up 14% versus its history, compared with RKLB at down 85%.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
IVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +2.9M shares |
| 1 year | +317% | +9M shares |
| 3 years | +519% | +9.9M shares |
| 5 years | +1212% | +10.9M shares |
| Available history | +2594% | +11.4M shares |
IVDA has 12M diluted shares, up 317% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has the edge over IVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IVDA Net Leverage
IVDA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.2 | Neutral |
| Stochastic | 4.0 | Oversold |
IVDA's weekly RSI is 37 (neutral) and its Stochastic is 4 (oversold).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
IVDA PE vs Industrials Sector
IVDA has no meaningful PE right now: it lost money over the past year.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
IVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.24 | 17% below |
| 20 week MA | $0.28 | 29% below |
| 50 week MA | $0.42 | 52% below |
| 100 week MA | $1.35 | 85% below |
| 200 week MA | $3.78 | 95% below |
IVDA is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB has the edge over IVDA on trend strength, trading above more of its moving averages.
IVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.8 | $32.0 | +47% |
| 2021 | $32.0 | $128.6 | +302% |
| 2022 | $128.6 | $4.64 | -96% |
| 2023 | $4.64 | $5.07 | +9.3% |
| 2024 | $5.07 | $5.53 | +9.1% |
| 2025 | $5.53 | $0.89 | -84% |
| 2026 YTD | $0.89 | $0.20 | -78% |
IVDA's yearly returns have swung widely, from +302% in 2021 to −96% in 2022. It's down 78% so far in 2026.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB has the edge over IVDA on returns for 2026, with the stronger performance.